🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the effort against drug-resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating around the world, with figures suggesting in excess of 82 million instances per year. Particularly high rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This authorization signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Outcomes and Global Access

According to findings detailed in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to license and sell the drug in numerous regions with limited resources.

Medical professionals on the front lines have expressed hope. Having a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.